Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis

  title={Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis},
  author={J{\"u}rgen De Fruyt and Ellen Deschepper and Kurt Audenaert and Eric Louis Constant and Michela Floris and William Pitchot and Pascal Sienaert and Daniel Souery and Stephan Claes},
  journal={Journal of Psychopharmacology},
  pages={603 - 617}
Depressive symptoms and episodes dominate the course of bipolar disorder. However, the therapeutic armamentarium for bipolar depression is limited. Recent evidence points to the efficacy of second generation antipsychotics (SGAs) for the treatment of bipolar depression. We conducted a systematic review and meta-analysis of the efficacy and safety of SGAs (randomized, double-blind, placebo-controlled trials; used in monotherapy) in the treatment of adult patients with bipolar depression… 

Figures and Tables from this paper

A systematic review of the evidence for the treatment of acute depression in bipolar I disorder

Evidence for the acute treatment of depression in bipolar I disorder is examined, focusing on double-blind, placebo-controlled studies with a definite primary outcome measure and published in peer review journals, to better understand the role of antidepressants.

Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder: A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials.

All medications studied in bipolar disorder were relatively well tolerated during different phases of treatment; however, the risk for short- and long-term WG and somnolence varied widely among included psychotropics.

Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials

There was a statistically significant higher risk of EPS-related AEs and a slight increase in mean body weight with cariprazine, and further clinical and post-marketing pharmacovigilance studies are needed to investigate the long-term safety of carIPrazine.

Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry

A systematic review of the available data concerning the efficacy of medication treatment of bipolar disorder (BP) suggests that lithium, first and second generation antipsychotics and valproate and carbamazepine are efficacious in the treatment of acute mania.

Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis.

Antipsychotic switching in bipolar disorders: a systematic review.

A comprehensive, computerized literature search using terms related to antipsychotic switching in BD in the PubMed/Medline, PsycINFO, CINAHL database; the Cochrane Library and the web returned 4160 articles, of which 8 studies were included.

The preclinical discovery and development of quetiapine for the treatment of mania and depression

Pre-clinical studies on QTP’s anti-manic effects are still scarce, and the role of the QTP metabolite norquetiapine in modulating non-neurotransmitter systems also needs to be further addressed.

Overview of antidepressant treatment of bipolar depression.

Overall efficacy was significantly greater with antidepressants than with placebo-treatment and not less than was found in trials for unipolar major depression, and risks of non-spontaneous mood-switching specifically associated with antidepressant treatment are less than appears to be widely believed.

Treatment of bipolar disorder




Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.

Some modern antipsychotics (quetiapine and olanzapine) have demonstrated efficacy in bipolar depressive patients from week 1 onwards and Rapid onset of action seems to be a common feature of atypical antipsychotic in bipolar depression.

Clinical highlights in bipolar depression: focus on atypical antipsychotics.

Subpopulation analyses suggest that quetiapine monotherapy and the olanzapine plus fluoxetine combination appear to be effective in treating depression in patients with a rapid-cycling course, and the magnitude of improvement in depressive symptoms in the bipolar I population appears to be larger for queto- monotherapy.

Bipolar depression: a new role for atypical antipsychotics?

  • P. Keck
  • Psychology, Medicine
    Bipolar disorders
  • 2005
Results from an 8-week, randomized placebo-controlled trial in patients with bipolar I and II disorder who were experiencing a bipolar depressive episode showed that quetiapine had significantly greater efficacy compared with placebo in improving the core symptoms of depression, including suicidal thoughts.

Atypical antipsychotics in bipolar disorder: systematic review of randomised trials

Atypical antipsychotics are effective in treating both phases of bipolar disorder compared with placebo, and as effective as established drug therapies.

The armamentarium of treatments for bipolar disorder: a review of the literature.

A growing role for atypical antipsychotics in the treatment of bipolar disorder is suggested and further data are anticipated.

Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.

Combining SGAs and MSs is the most efficacious treatment of acute mania, and adding antipsychotic agents to MS treatment was significantly more effective than treatment with MSs alone.

Effectiveness of adjunctive antidepressant treatment for bipolar depression.

The use of adjunctive, standard antidepressant medication, as compared with the use of mood stabilizers, was not associated with increased efficacy or with increased risk of treatment-emergent affective switch.

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.

Olanzapine is more effective than placebo, and combined olanzapine-fluoxetine isMore effective than olanZapine and placebo in the treatment of bipolar I depression without increased risk of developing manic symptoms.

Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.

Quetiapine monotherapy shows efficacy in treating anxiety symptoms in bipolar I depression; however, the anxiolytic effects in bipolar II disorder require further investigation.

Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.

Post hoc secondary analyses suggest that lamotrigine may be superior to inositol and risperidone in improving treatment-resistant bipolar depression.